latest update:
[TrialBase DB]

trial summary · NCT07153055

Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

Phase I/II Trial of Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

Trial record from the TrialBase DB dataset, status RECRUITING, condition Small Cell Lung Cancer ( SCLC ), sponsored by Misty Shields. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07153055phase PHASE1/PHASE2enrollment 16start 2027-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This open-label, Phase I/II trial is studying the safety and effectiveness of an experimental drug combination, lurbinectedin with osimertinib, against a rare type of cancer known as transformed small cell lung cancer (SCLC).

Source record: https://clinicaltrials.gov/study/NCT07153055

Facts

registry idNCT07153055
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionSmall Cell Lung Cancer ( SCLC )
sponsorMisty Shields
sponsor classOTHER
enrollment16
start date2027-01
primary completion2029-04
completion2029-10
results postednot reported

Conditions

  • Small Cell Lung Cancer ( SCLC )
  • Transformed Small Cell Lung Cancer

Interventions

  • Lurbinectedin
  • Osimertinib

Countries

  • United States

Intervention types: DRUG

Work with this record